LNCR
MCID: LNG032
MIFTS: 99

Lung Cancer (LNCR)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 57 12 75 25 74 29 6 43 3 15
Non-Small Cell Lung Cancer 12 75 37 29 6 15
Non-Small Cell Lung Carcinoma 12 15 17 72
Lung Carcinoma 12 55 15 17
Lung Cancer, Protection Against 57 29 6
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 57 13
Lung Cancer, Susceptibility to 57 6
Malignant Neoplasm of Lung 25 72
Nonsmall Cell Lung Cancer 57 74
Alveolar Cell Carcinoma 74 29
Carcinoma of Lung 12 72
Lung Neoplasms 25 72
Lung Neoplasm 12 75
Nsclc 12 55
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 57
Nonsmall Cell Lung Cancer, Susceptibility to 57
Nonsmall Cell Lung Cancer, Somatic 57
Primary Malignant Neoplasm of Lung 72
Bronchioloalveolar Adenocarcinoma 72
Adenocarcinoma of Lung, Somatic 57
Carcinoma, Non-Small-Cell Lung 44
Lung Non-Small Cell Carcinoma 12
Carcinoma Non-Small Cell Lung 55
Cancer, Lung, Non-Small Cell 40
Lung Cancer, Resistance to 57
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 74
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Lung Cancer, Somatic 57
Malignant Lung Tumor 25
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Neoplasm of Lung 29
Lung Carcinomas 15
Cancer of Lung 12
Lung Cancers 15
Cancer, Lung 40
Cancer Lung 55
Lncr 74

Characteristics:

OMIM:

57
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
genes associated with susceptibility to lung cancer, e.g., faslg (), fas (), chrna5 (), chrna3 ()
genes associated with a protection against lung cancer, e.g., casp8 (), cyp2a6 ()
mutations in egfr (131550) are associated with altered response to treatment with tyrosine kinase inhibitors



Classifications:



External Ids:

Disease Ontology 12 DOID:1324 DOID:3905 DOID:3908
OMIM 57 211980
KEGG 37 H00014
NCIt 50 C2926 C4878
UMLS 72 C0007120 C0007131 C0024121 more

Summaries for Lung Cancer

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked. Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent. Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years. Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.

MalaCards based summary : Lung Cancer, also known as non-small cell lung cancer, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Iodine and Terbutaline have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are alveolar cell carcinoma and Decreased viability

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

OMIM : 57 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

MedlinePlus : 43 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the lungs, it is called lung cancer. Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types called small cell and non-small cell. These types of lung cancer grow differently and are treated differently. Non-small cell lung cancer is more common than small cell lung cancer.

KEGG : 37
Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.

UniProtKB/Swiss-Prot : 74 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 75 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1814)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 37.7 PRKN PIK3CA NRAS MAP2K1 KRAS ERBB2
2 small cell cancer of the lung 36.3 PTEN PIK3CA KIT EGFR
3 lung squamous cell carcinoma 35.9 PTEN PIK3CA KRAS EGFR BRAF ALK
4 adenocarcinoma 35.3 PTEN PIK3CA MAP2K1 KRAS KIT ERBB2
5 lung adenoid cystic carcinoma 35.2 PIK3CA KRAS KIT DDR2 ALK
6 endometrial cancer 35.0 PTEN PIK3CA KRAS KIT ERBB2 EGFR
7 colorectal cancer 34.6 PTEN PPP2R1B PIK3CA NRAS MAP2K1 KRAS
8 breast cancer 34.3 SLC22A18 PTEN PIK3CA KRAS KIT ERBB2
9 squamous cell carcinoma 34.3 PTEN PIK3CA ERBB2 EGFR DDR2 BRAF
10 ovarian cancer 34.0 PTEN PRKN PIK3CA KRAS FASLG ERBB2
11 esophageal cancer 33.9 PTEN PIK3CA KRAS FASLG ERBB2 EGFR
12 small cell carcinoma 33.8 PTEN KIT EGFR
13 hepatocellular carcinoma 33.8 PTEN PIK3CA NRAS MAP2K1 KRAS FASLG
14 exanthem 33.7 KRAS ERBB2 EGFR
15 gastric adenocarcinoma 33.7 PTEN PIK3CA NRAS KRAS KIT FASLG
16 glioblastoma 33.6 PTEN PIK3CA NRAS ERBB2 EGFR BRAF
17 adenosquamous carcinoma 33.5 PIK3CA KRAS KIT EGFR
18 brain cancer 33.3 PTEN PIK3CA NRAS EGFR CASP8 BRAF
19 breast adenocarcinoma 33.2 SLC22A18 PTEN PIK3CA KRAS ERBB2 EGFR
20 myeloma, multiple 33.2 NRAS KRAS KIT CASP8 BRAF
21 cervical cancer 33.1 PTEN PPP2R1B PIK3CA IRF1 ERBB2 CASP8
22 gastric cancer 33.1 PTEN PIK3CA KRAS IRF1 ERBB2 EGFR
23 adenoid cystic carcinoma 33.0 PTEN PIK3CA KRAS KIT ERBB2
24 acneiform dermatitis 33.0 PIK3CA NRAS MAP2K1 KRAS ERBB2 EGFR
25 cholangiocarcinoma 33.0 PTEN PIK3CA KRAS ERBB2 EGFR BRAF
26 glioma 32.9 PTEN PIK3CA ERBB2 EGFR BRAF
27 glioblastoma multiforme 32.9 PTEN PIK3CA ERBB2 EGFR
28 lymphoma, non-hodgkin, familial 32.9 PIK3CA NRAS CASP8 BRAF ALK
29 medulloblastoma 32.8 PTEN PIK3CA NRAS MAP2K1 ERBB2 EGFR
30 squamous cell carcinoma, head and neck 32.8 PTEN PIK3CA ERBB2 EGFR BRAF
31 prostate cancer 32.8 PTEN PIK3CA MAP2K1 KRAS ERBB2 EGFR
32 bladder urothelial carcinoma 32.8 PIK3CA NRAS MAP2K1 KRAS KIT ERBB2
33 gastrointestinal stromal tumor 32.8 PTEN KRAS KIT EGFR BRAF
34 carcinosarcoma 32.8 PTEN PIK3CA KRAS KIT ERBB2
35 adenosquamous lung carcinoma 32.7 PIK3CA KRAS ERBB2 EGFR DDR2 ALK
36 mucinous adenocarcinoma 32.7 KRAS EGFR ALK
37 undifferentiated pleomorphic sarcoma 32.7 PIK3CA KRAS KIT
38 transitional cell carcinoma 32.6 PTEN ERBB2 EGFR BRAF
39 gastrointestinal system cancer 32.5 PTEN PIK3CA KRAS KIT ERBB2 EGFR
40 oral cavity cancer 32.3 PTEN PIK3CA ERBB2 EGFR CASP8
41 respiratory system cancer 32.3 PTEN PIK3CA KRAS ERBB2 EGFR ALK
42 renal cell carcinoma, papillary, 1 32.3 PTEN PIK3CA NRAS KIT ERBB2 BRAF
43 melanoma, cutaneous malignant 1 32.2 PTEN PIK3CA NRAS MAP2K1 KIT BRAF
44 lymphoproliferative syndrome 32.2 NRAS FASLG CASP8
45 ewing sarcoma 32.1 KIT IRF1 FASLG EGFR CASP8 ALK
46 paronychia 32.1 KRAS EGFR
47 uterine carcinosarcoma 32.1 PTEN PIK3CA KIT ERBB2 EGFR
48 ovarian serous cystadenocarcinoma 32.1 PIK3CA NRAS ERBB2 BRAF
49 differentiated thyroid carcinoma 32.1 NRAS KRAS EGFR BRAF ALK
50 colorectal adenocarcinoma 32.1 KRAS EGFR BRAF

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Human phenotypes related to Lung Cancer:

32
# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 32 HP:0006519

Symptoms via clinical synopsis from OMIM:

57
Respiratory Lung:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Neoplasia:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Clinical features from OMIM:

211980

UMLS symptoms related to Lung Cancer:


fever, dyspnea, hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.09 BRAF KRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.09 KRAS
3 Decreased viability GR00221-A-1 11.09 KIT KRAS EGFR PIK3CA ALK DDR2
4 Decreased viability GR00221-A-2 11.09 KRAS MAP3K8 PIK3CA DDR2
5 Decreased viability GR00221-A-3 11.09 MAP3K8 NRAS ERBB2
6 Decreased viability GR00221-A-4 11.09 BRAF MAP3K8 EGFR PIK3CA ALK DDR2
7 Decreased viability GR00301-A 11.09 BRAF KIT KRAS MAP3K8
8 Decreased viability GR00342-S-1 11.09 MAP3K8
9 Decreased viability GR00342-S-2 11.09 MAP3K8
10 Decreased viability GR00342-S-3 11.09 MAP3K8
11 Decreased viability GR00381-A-1 11.09 BRAF KRAS
12 Decreased viability GR00402-S-2 11.09 BRAF KIT KRAS MAP3K8 EGFR PIK3CA
13 Decreased viability in esophageal squamous lineage GR00235-A 10.06 BRAF DDR2 ERBB2 ERCC6 FASLG KIT
14 Decreased cell migration GR00055-A-1 9.95 ALK BRAF DDR2 EGFR KRAS PIK3CA
15 Decreased substrate adherent cell growth GR00193-A-1 9.88 KIT
16 Decreased substrate adherent cell growth GR00193-A-2 9.88 ALK EGFR KIT MAP3K8
17 Decreased substrate adherent cell growth GR00193-A-4 9.88 KIT
18 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.83 EGFR ERBB2 MAP3K8 NRAS PTEN
19 Increased cell migration GR00055-A-3 9.65 BRAF DDR2 EGFR KRAS PIK3CA
20 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.63 BRAF DDR2 EGFR
21 Reduced mammosphere formation GR00396-S 9.5 BRAF EGFR FASLG KRAS MAP3K8 NRAS
22 Increased cell viability after pRB stimulation GR00230-A-1 9.46 DDR2 EGFR ERBB2 KIT
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CASP8 ERCC6 PRKN PTEN SLC22A18
24 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BRAF CASP8 ERCC6 FASLG PRKN PTEN

MGI Mouse Phenotypes related to Lung Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
2 cardiovascular system MP:0005385 10.5 BRAF CASP8 DDR2 EGFR ERBB2 FASLG
3 homeostasis/metabolism MP:0005376 10.5 ALK BRAF CASP8 DDR2 EGFR ERBB2
4 growth/size/body region MP:0005378 10.47 ALK BRAF CASP8 DDR2 EGFR ERBB2
5 integument MP:0010771 10.45 ALK BRAF CASP8 DDR2 EGFR ERBB2
6 endocrine/exocrine gland MP:0005379 10.44 ALK BRAF CASP8 DDR2 EGFR ERBB2
7 mortality/aging MP:0010768 10.44 ALK BRAF CASP8 DDR2 EGFR ERBB2
8 neoplasm MP:0002006 10.38 ALK BRAF CASP8 DDR2 EGFR ERBB2
9 immune system MP:0005387 10.34 BRAF CASP8 EGFR ERCC6 FASLG IRF1
10 hematopoietic system MP:0005397 10.32 BRAF CASP8 EGFR ERCC6 FASLG IRF1
11 digestive/alimentary MP:0005381 10.31 BRAF EGFR ERBB2 FASLG KIT KRAS
12 embryo MP:0005380 10.3 BRAF CASP8 EGFR ERBB2 KIT KRAS
13 nervous system MP:0003631 10.3 ALK BRAF CASP8 DDR2 EGFR ERBB2
14 muscle MP:0005369 10.24 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
15 craniofacial MP:0005382 10.22 BRAF DDR2 EGFR ERBB2 KIT KRAS
16 limbs/digits/tail MP:0005371 10.19 BRAF DDR2 EGFR ERBB2 ERCC6 KIT
17 liver/biliary system MP:0005370 10.18 BRAF CASP8 EGFR ERCC6 FASLG KIT
18 normal MP:0002873 10.14 BRAF EGFR ERBB2 FASLG IRF1 KIT
19 hearing/vestibular/ear MP:0005377 10.06 BRAF EGFR ERCC6 KIT KRAS MAP2K1
20 reproductive system MP:0005389 10.03 ALK BRAF DDR2 EGFR ERBB2 FASLG
21 no phenotypic analysis MP:0003012 9.98 DDR2 EGFR KIT KRAS NRAS PIK3CA
22 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KIT
23 pigmentation MP:0001186 9.91 ALK BRAF EGFR KIT KRAS NRAS
24 respiratory system MP:0005388 9.85 ALK BRAF CASP8 EGFR ERBB2 FASLG
25 skeleton MP:0005390 9.83 ALK BRAF DDR2 EGFR ERBB2 ERCC6
26 vision/eye MP:0005391 9.4 ALK BRAF DDR2 EGFR ERCC6 FASLG

Drugs & Therapeutics for Lung Cancer

DrugBank drugs 16 :

(show all 9)
# Drug Name Indication DrugBank ID
1 Cisplatin For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. DB00515
2 Cyclophosphamide Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. DB00531
3 Entrectinib DB11986
4 Erlotinib Erlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label]. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label]. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label] DB00530
5 Etoposide For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. DB00773
6 Irinotecan For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. DB00762
7 Mitomycin For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. DB00305
8 Paclitaxel Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. DB01229
9 Vinblastine For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma. DB00570

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 919)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4 7553-56-2 807
2
Terbutaline Approved Phase 4 23031-25-6 5403
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Dalteparin Approved Phase 4 9005-49-6
5
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
6
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
7
Caffeine Approved Phase 4 58-08-2 2519
8
Budesonide Approved Phase 4 51333-22-3 63006 5281004
9
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
10
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
11
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Norepinephrine Approved Phase 4 51-41-2 439260
14
tannic acid Approved Phase 4 1401-55-4
15
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
16
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
17
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
18
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
21
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
22
Etoposide Approved Phase 4 33419-42-0 36462
23
Fosaprepitant Approved Phase 4 172673-20-0 219090
24
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
25
Ondansetron Approved Phase 4 99614-02-5 4595
26
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
27
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
28
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
29
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
30
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
31
Epicatechin Investigational Phase 4 35323-91-2, 490-46-0 72276
32
Theobromine Investigational Phase 4 83-67-0 5429
33
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
34 Flurbiprofen axetil Investigational Phase 4 91503-79-6
35 Anti-Infective Agents, Local Phase 4
36 cadexomer iodine Phase 4
37
Salmeterol xinafoate Phase 4 94749-08-3 56801
38 Fluticasone-Salmeterol Drug Combination Phase 4
39 Cholinergic Agents Phase 4
40 Nicotinic Agonists Phase 4
41 Analgesics, Opioid Phase 4
42 Lipid Regulating Agents Phase 4
43 Hypolipidemic Agents Phase 4
44 Anticholesteremic Agents Phase 4
45 Wakefulness-Promoting Agents Phase 4
46 N-monoacetylcystine Phase 4
47 Expectorants Phase 4
48 Carotenoids Phase 4
49 Provitamins Phase 4
50 Opiate Alkaloids Phase 4

Interventional clinical trials:

(show top 50) (show all 7772)
# Name Status NCT ID Phase Drugs
1 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
2 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
3 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
4 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
5 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
6 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
7 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
8 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
9 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
10 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
11 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
12 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
13 A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar(rh Recombined Endostatin)With Single Docetaxel In NSCLC Patients Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
14 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
15 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
16 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
17 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
18 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
19 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
20 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
21 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
22 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
23 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
24 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
25 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
26 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
27 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
28 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
29 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
30 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
31 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
32 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
33 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
34 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
35 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
37 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
38 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
39 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
40 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
41 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
42 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
43 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
44 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
45 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
46 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
47 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
48 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
49 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
50 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Afatinib
afatinib dimaleate
Carboplatin
Carmustine
ceritinib
Cholecalciferol
Cisplatin
Cisplatin
CISPLATIN PWDR
crizotinib
Cyclophosphamide
Cyclophosphamide
docetaxel
Entrectinib
erlotinib
Erlotinib
Etoposide
Etoposide
etoposide phosphate
gefitinib
hydroxyurea
Ifosfamide
irinotecan
Irinotecan
Irinotecan hydrochloride
Lomustine
Methotrexate
Methotrexate Sodium
Mitomycin
Paclitaxel
Paclitaxel
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Teniposide
Topotecan
Topotecan Hydrochloride
trametinib
Vinblastine
Vinblastine
Vinblastine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Cancer 29 BRAF CASP8 CYP2A6 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA PPP2R1B PRKN SLC22A18
3 Lung Cancer, Protection Against 29
4 Alveolar Cell Carcinoma 29
5 Neoplasm of Lung 29

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

41
Lung, Brain, Lymph Node, Breast, Testes, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

19
Lung

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 58908)
# Title Authors PMID Year
1
CYP2A6 gene deletion reduces susceptibility to lung cancer. 9 38 8 71
10441482 1999
2
Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. 9 8 71
15937082 2005
3
Missense mutations of the BRAF gene in human lung adenocarcinoma. 9 8 71
12460919 2002
4
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. 8 71
17450141 2007
5
High frequency of mutations of the PIK3CA gene in human cancers. 8 71
15016963 2004
6
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. 8 71
11745231 2001
7
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. 8 71
10217419 1999
8
Screening for epidermal growth factor receptor mutations in lung cancer. 9 38 8
19692684 2009
9
DNA methylation markers and early recurrence in stage I lung cancer. 9 38 8
18337602 2008
10
LKB1 modulates lung cancer differentiation and metastasis. 9 38 8
17676035 2007
11
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 9 38 8
17625570 2007
12
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 9 38 8
15118073 2004
13
BRAF and RAS mutations in human lung cancer and melanoma. 9 38 71
12460918 2002
14
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. 9 38 8
10580025 1999
15
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. 38 71
24846033 2014
16
National Working Group Meeting on ALK diagnostics in lung cancer. 38 71
24673736 2014
17
C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer. 38 8
21499297 2011
18
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). 9 38 88
20223231 2010
19
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. 9 38 88
19597153 2009
20
Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. 38 8
19100526 2009
21
MicroRNA-183 regulates Ezrin expression in lung cancer cells. 9 38 88
18840437 2008
22
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. 9 38 88
18922928 2008
23
Lung cancer. 38 8
18815398 2008
24
Detection of mutations in EGFR in circulating lung-cancer cells. 38 8
18596266 2008
25
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. 9 38 88
18246122 2008
26
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 9 8
17463250 2007
27
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 9 71
15608678 2005
28
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 9 8
15329413 2004
29
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 38 71
15457249 2004
30
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. 9 8
12802680 2003
31
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. 38 8
12748244 2003
32
Association between the p21 codon 31 A1 (arg) allele and lung cancer. 9 8
8807325 1996
33
Genetic component of lung cancer: cohort study of twins. 38 8
7914565 1994
34
Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy. 38 17
31301483 2019
35
Treatment rationale and design of the induction chemotherapy and adjuvant thoracic radiation in resectable N2-3A/3B non-small cell lung cancer (ICAT) study. 38 17
31277165 2019
36
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 71
26266975 2015
37
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 71
26266985 2015
38
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. 71
25311215 2014
39
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. 8
25301631 2014
40
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. 8
25301630 2014
41
Comprehensive molecular profiling of lung adenocarcinoma. 8
25079552 2014
42
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. 71
24868098 2014
43
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. 71
24627688 2014
44
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 71
23562183 2013
45
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group. 71
23667368 2013
46
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 71
23100325 2013
47
Comprehensive genomic characterization of squamous cell lung cancers. 8
22960745 2012
48
A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. 8
22883146 2012
49
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. 8
22751098 2012
50
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 71
22658544 2012

Variations for Lung Cancer

ClinVar genetic disease variations for Lung Cancer:

6 (show top 50) (show all 236)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CASP8 NM_001228.4(CASP8): c.-937_-932del deletion protective rs3834129 2:202097532-202097537 2:201232809-201232814
2 CYP2A6 CYP2A6*4A deletion protective
3 EGFR NM_005228.5(EGFR): c.2155G> C (p.Gly719Arg) single nucleotide variant Likely pathogenic,drug response rs28929495 7:55241707-55241707 7:55174014-55174014
4 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
5 KRAS NM_004985.5(KRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
6 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
7 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
8 KRAS NM_004985.5(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
9 BRAF NM_004333.6(BRAF): c.1405_1407del (p.Gly469del) deletion Pathogenic rs397516890 7:140481401-140481403 7:140781601-140781603
10 BRAF NM_004333.6(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
11 ERBB2 NM_004448.3(ERBB2): c.2331_2339dup (p.Gly778_Pro780dup) duplication Pathogenic rs397516981 17:37881002-37881010 17:39724749-39724757
12 KRAS NM_004985.5(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
13 KRAS NM_004985.5(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
14 EGFR NM_005228.5(EGFR): c.2127_2129del (p.Glu709_Thr710delinsAsp) deletion Pathogenic rs397517086 7:55241679-55241681 7:55173986-55173988
15 IRF1 NM_002198.3(IRF1): c.31T> C (p.Trp11Arg) single nucleotide variant Pathogenic rs121912470 5:131825140-131825140 5:132489448-132489448
16 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
17 EGFR NM_005228.5(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic rs121913428 7:55241708-55241708 7:55174015-55174015
18 EGFR NM_005228.5(EGFR): c.2303G> T (p.Ser768Ile) single nucleotide variant Pathogenic rs121913465 7:55249005-55249005 7:55181312-55181312
19 EGFR NM_005228.5(EGFR): c.2303_2304delinsTT (p.Ser768Ile) indel Pathogenic rs397517108 7:55249005-55249006 7:55181312-55181313
20 EGFR NM_005228.5(EGFR): c.2310_2311insGGGTTG (p.Asn771_Pro772insGlyLeu) insertion Pathogenic rs397517111 7:55249012-55249013 7:55181319-55181320
21 EGFR NM_005228.5(EGFR): c.2312_2314dup (p.Pro772_His773insHis) duplication Pathogenic rs397517112 7:55249014-55249016 7:55181321-55181323
22 EGFR NM_005228.5(EGFR): c.2500G> T (p.Val834Leu) single nucleotide variant Pathogenic rs397517127 7:55259442-55259442 7:55191749-55191749
23 PIK3CA NM_006218.4(PIK3CA): c.3073A> G (p.Thr1025Ala) single nucleotide variant Pathogenic rs397517202 3:178952018-178952018 3:179234230-179234230
24 NRAS NM_002524.5(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
25 NRAS NM_002524.5(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
26 BRAF NM_004333.6(BRAF): c.735A> C (p.Leu245Phe) single nucleotide variant Pathogenic rs397507466 7:140501337-140501337 7:140801537-140801537
27 NRAS NM_002524.5(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
28 NRAS NM_002524.5(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
29 MAP2K1 NM_002755.3(MAP2K1): c.199G> A (p.Asp67Asn) single nucleotide variant Pathogenic rs727504317 15:66727483-66727483 15:66435145-66435145
30 PTEN NM_000314.7(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 10:89717672-89717672 10:87957915-87957915
31 PPP2R1B NM_181699.3(PPP2R1B): c.269G> A (p.Gly90Asp) single nucleotide variant Pathogenic rs1805076 11:111635566-111635566 11:111764842-111764842
32 SLC22A18 NM_002555.6(SLC22A18): c.698C> T (p.Ser233Phe) single nucleotide variant Pathogenic rs121909071 11:2939260-2939260 11:2918030-2918030
33 PRKN NM_004562.3(PRKN): c.823C> T (p.Arg275Trp) single nucleotide variant Pathogenic rs34424986 6:162206852-162206852 6:161785820-161785820
34 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
35 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
36 BRAF NM_004333.6(BRAF): c.1789C> G (p.Leu597Val) single nucleotide variant Pathogenic rs121913369 7:140453146-140453146 7:140753346-140753346
37 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
38 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
39 KRAS NM_004985.5(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
40 KRAS NM_004985.5(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 12:25398281-25398281 12:25245347-25245347
41 KRAS NM_004985.5(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
42 KRAS NM_004985.5(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
43 KRAS NM_004985.5(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
44 KRAS NM_004985.5(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 12:25362838-25362838 12:25209904-25209904
45 BRAF NM_004333.6(BRAF): c.1415A> G (p.Tyr472Cys) single nucleotide variant Pathogenic rs1057519719 7:140481393-140481393 7:140781593-140781593
46 BRAF NM_004333.6(BRAF): c.1405_1406delinsTT (p.Gly469Leu) indel Pathogenic rs1057519720 7:140481402-140481403 7:140781602-140781603
47 KRAS NM_004985.5(KRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic rs1057519725 12:25378561-25378561 12:25225627-25225627
48 KRAS NM_004985.5(KRAS): c.38G> C (p.Gly13Ala) single nucleotide variant Pathogenic rs112445441 12:25398281-25398281 12:25245347-25245347
49 KRAS NM_004985.5(KRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
50 DDR2 NM_006182.4(DDR2): c.2304T> A (p.Ser768Arg) single nucleotide variant Pathogenic rs267598140 1:162748390-162748390 1:162778600-162778600

UniProtKB/Swiss-Prot genetic disease variations for Lung Cancer:

74
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly466Val VAR_018512 rs121913351
2 BRAF p.Leu597Arg VAR_018513 rs121913366
3 MXRA5 p.Ser862Asn VAR_072408
4 SLC22A18 p.Ser233Phe VAR_024062 rs121909071

Cosmic variations for Lung Cancer:

9 (show top 50) (show all 14696)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM7410942 ZSWIM8 lung,NS,carcinoma,adenocarcinoma c.2505G>A p.G835G 10:73799190-73799190 183
2 COSM7411331 ZSWIM5 lung,NS,carcinoma,adenocarcinoma c.2363C>A p.P788H 1:45034398-45034398 183
3 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 183
4 COSM7411164 ZPBP lung,NS,carcinoma,adenocarcinoma c.966C>G p.I322M 7:49937618-49937618 183
5 COSM7411425 ZPBP lung,NS,carcinoma,adenocarcinoma c.706G>T p.V236F 7:50031092-50031092 183
6 COSM2768407 ZNF800 lung,NS,carcinoma,adenocarcinoma c.1606C>T p.R536* 7:127373730-127373730 183
7 COSM7411930 ZNF687 lung,NS,carcinoma,adenocarcinoma c.2361C>G p.H787Q 1:151289161-151289161 183
8 COSM7411692 ZNF608 lung,NS,carcinoma,adenocarcinoma c.2023G>A p.V675I 5:124648361-124648361 183
9 COSM7412390 ZNF536 lung,NS,carcinoma,adenocarcinoma c.2770A>T p.S924C 19:30548389-30548389 183
10 COSM1388126 ZNF521 lung,NS,carcinoma,adenocarcinoma c.2365G>A p.G789S 18:25225553-25225553 183
11 COSM7411528 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1122C>T p.S374S 16:49638030-49638030 183
12 COSM7411524 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1436C>T p.A479V 16:49637716-49637716 183
13 COSM7411526 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1157C>T p.S386F 16:49637995-49637995 183
14 COSM7411530 ZNF423 lung,NS,carcinoma,adenocarcinoma c.634C>A p.H212N 16:49638518-49638518 183
15 COSM3712145 ZNF423 lung,NS,carcinoma,adenocarcinoma c.609C>G p.F203L 16:49638543-49638543 183
16 COSM7411916 ZNF326 lung,NS,carcinoma,adenocarcinoma c.544G>A p.E182K 1:90007679-90007679 183
17 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 183
18 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 183
19 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 183
20 COSM7412277 ZIC5 lung,NS,carcinoma,adenocarcinoma c.1583G>A p.C528Y 13:99965786-99965786 183
21 COSM7411445 ZHX1 lung,NS,carcinoma,adenocarcinoma c.1640C>T p.T547M 8:123254307-123254307 183
22 COSM7411890 ZFX lung,NS,carcinoma,adenocarcinoma c.919C>T p.Q307* 23:24207834-24207834 183
23 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 183
24 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 183
25 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 183
26 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 183
27 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 183
28 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 183
29 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 183
30 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 183
31 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 183
32 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 183
33 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 183
34 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 183
35 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 183
36 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 183
37 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 183
38 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 183
39 COSM6940635 ZFHX3